<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vedomostiregmed</journal-id><journal-title-group><journal-title xml:lang="ru">Регуляторные исследования и экспертиза лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Regulatory Research and Medicine Evaluation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-3062</issn><issn pub-type="epub">3034-3453</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30895/1991-2919-2025-15-4-444-450</article-id><article-id custom-type="elpub" pub-id-type="custom">vedomostiregmed-774</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГЛАВНАЯ ТЕМА: РАДИОФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ: НА ПУТИ К ПАЦИЕНТУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MAIN TOPIC: RADIOPHARMACEUTICALS ON THEIR WAY TO THE PATIENTS</subject></subj-group></article-categories><title-group><article-title>Разработка и валидация методики определения элементных примесей в флудезоксиглюкозе (18F) методом масс-спектрометрии с индуктивно-связанной плазмой</article-title><trans-title-group xml:lang="en"><trans-title>Elemental Impurity Detection Technique in Fluorodeoxyglucose (18F) Using Inductively Coupled Plasma Mass Spectrometry: Development and Validation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2125-6174</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Швецова</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shvetsova</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Швецова Юлия Николаевна.</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Yulia N. Shvetsova.</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">shvetsovajn@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7488-7204</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ерина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Erina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ерина Алина Андреевна.</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Alina A. Erina.</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">erina@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9440-0950</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щукин</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchukin</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щукин Виктор Михайлович - канд. фарм. наук.</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Viktor M. Shchukin - Cand. Sci. (Pharm.).</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">schukin@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9133-0835</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>Н. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuz'mina</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузьмина Наталия Евгеньевна - д-р хим. наук.</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Natalia E. Kuz’mina - Dr. Sci. (Chem.).</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">KuzminaN@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Centre for Expert Evaluation of Medicinal Products</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>08</month><year>2025</year></pub-date><volume>15</volume><issue>4</issue><fpage>444</fpage><lpage>450</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Швецова Ю.Н., Ерина А.А., Щукин В.М., Кузьмина Н.Е., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Швецова Ю.Н., Ерина А.А., Щукин В.М., Кузьмина Н.Е.</copyright-holder><copyright-holder xml:lang="en">Shvetsova Y.N., Erina A.A., Shchukin V.M., Kuz'mina N.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vedomostincesmp.ru/jour/article/view/774">https://www.vedomostincesmp.ru/jour/article/view/774</self-uri><abstract><sec><title>ВВЕДЕНИЕ</title><p>ВВЕДЕНИЕ. Производители отечественных радиофармацевтических лекарственных препаратов обязаны в ходе разработки и валидации производственного процесса определять в своей продукции содержание примесей Pb, As, Fe, а также других элементов, вносящих максимальный вклад в контаминацию препарата. На стадии предварительного мониторинга установлено, что такими элементами в препарате «Флудезоксиглюкоза (18F)» являются Al, Cu, Zn.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Разработка и валидация методики определения содержания элементов Al, As, Cu, Fe, Pb, Zn в флудезоксиглюкозе (18F) методом масс-спектрометрии с индуктивно связанной плазмой.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. Разработку методики проводили на модельной смеси, имитирующей состав флудезоксиглюкозы (18F). Для валидации использовали образец препарата с минимальным содержанием анализируемых примесей, к которому добавляли варьируемые количества стандартных растворов определяемых элементов. Содержание элементов определяли на масс-спектрометре Agilent 7900. Фиксировали интенсивность сигналов следующих изотопов (а.е.м.): 27Al, 57Fe, 63Cu, 66Zn, 75As, 208Pb.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Установлено, что органическая матрица не оказывает существенного влияния на результат элементного анализа. NaCl из-за матричного эффекта понижает открываемость элементов Al, Cu, Pb, Zn до уровня ниже 70%. При разбавлении модельной смеси в 10 раз открываемость анализируемых элементов составляет 90–101%. Коэффициенты корреляции линейных зависимостей «концентрация элемента — интенсивность сигнала» выше 0,99. Значения относительного стандартного отклонения (RSD) при оценке прецизионности не превышают 10%.</p></sec><sec><title>ВЫВОДЫ</title><p>ВЫВОДЫ. Разработана методика определения содержания Al, As, Cu, Fe, Pb, Zn в флудезоксиглюкозе (18F) методом масс-спектрометрии с индуктивно связанной плазмой, учитывающая на стадии пробоподготовки влияние компонентов матрицы на количественную оценку целевых элементов. Валидационные характеристики методики соответствуют фармакопейным требованиям.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>INTRODUCTION</title><p>INTRODUCTION. When developing and validating manufacturing of a product, Russian radiopharmaceutical manufacturers are required to detect ubiquitous impurities (Pb, As, Fe as well as other elements) causing contamination. At the stage of preliminary monitoring, Al, Cu, and Zn were found to most often contribute to fluorodeoxyglucose (18F) elemental contamination.</p></sec><sec><title>AIM</title><p>AIM. This study aimed to develop and validate a technique detecting Al, As, Cu, Fe, Pb, and Zn in fluorodeoxyglucose (18F) using inductively coupled plasma mass spectrometry (ICP-MS).</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS. The technique was developed on a model mixture simulating fluorodeoxyglucose (18F). A sample with minimum analysed impurities was used for validation; then varying amounts of standard analyte solutions were added. The content was determined using Agilent 7900 mass spectrometer. Signal intensities of the following isotopes (a.u.m.) were recorded: 27Al, 57Fe, 63Cu, 66Zn, 75As, and 208Pb.</p></sec><sec><title>RESULTS</title><p>RESULTS. The organic matrix was found to insignificantly affect elemental analysis. Due to matrix effect, NaCl reduced spike recovery of Al, Cu, Pb, and Zn to the level below 70%. When diluting model mixture tenfold, spike recovery of the analytes reached 90–101%. Correlation coefficients of element concentration — signal intensity linear dependences for the analytes exceeded 0.99. When estimating precision, RSD values did not exceed 10%.</p></sec><sec><title>CONCLUSIONS</title><p>CONCLUSIONS. A technique has been developed detecting Al, As, Cu, Fe, Pb, and Zn in fluorodeoxyglucose (18F) using ICP-MS. This technique considers influence of matrix components on quantification of target elements when preparing samples. Validation parameters of the technique comply with pharmacopoeial requirements.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>радиофармацевтические лекарственные препараты</kwd><kwd>флудезоксиглюкоза (18F)</kwd><kwd>элементные примеси</kwd><kwd>масс-спектрометрия с индуктивно связанной плазмой</kwd><kwd>валидация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>radiopharmaceuticals</kwd><kwd>fludeoxyglucose (18F)</kwd><kwd>elemental impurities</kwd><kwd>inductively coupled plasma mass spectrometry</kwd><kwd>validation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00001-25-00 на проведение прикладных научных исследований (номер государственного учета НИР 124022300127-0).</funding-statement><funding-statement xml:lang="en">The study was conducted by the Scientific Centre for Expert Evaluation of Medicinal Products as part of the applied research funded under State Assignment No. 056-00026-24-01 (R&amp;D Registry No. 124022300127-0).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Arnaout A, Varela NP, Allarakhia M, et al. Baseline staging imaging for distant metastasis in women with stages I, II, and III breast cancer. Curr Oncol. 2020;27(2):e123–45. https://doi.org/10.3747/co.27.6147</mixed-citation><mixed-citation xml:lang="en">Arnaout A, Varela NP, Allarakhia M, et al. Baseline staging imaging for distant metastasis in women with stages I, II, and III breast cancer. Curr Oncol. 2020;27(2):e123–45. https://doi.org/10.3747/co.27.6147</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Долгушин МБ, Михайлов АИ, Гордеев СС. Роль ПЭТ/КТ с 18F-фтордезоксиглюкозой в выявлении прогрессирования колоректального рака у асимптоматических пациентов с повышенным уровнем раково-эмбрионального антигена (обзор литературы). Онкологическая колопроктология 2019;9(2):11–5. https://doi.org/10.17650/2220-3478-2019-9-2-11-15</mixed-citation><mixed-citation xml:lang="en">Dolgushin MB, Mikhaylov AI, Gordeev SS. The role of PET/CT with 18F-fluorodeoxyglucose in detecting the progression of colorectal cancer in asymptomatic patients with elevated level of сarcinoembryonic antigen (literature review). Colorectal Oncology. 2019;9(2):11–5 (In Russ.). https://doi.org/10.17650/2220-3478-2019-9-2-11-15</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vali R, Alessio A, Balza R, et al. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/ CT for Oncology 1.0. J Nucl Med. 2021;62(1):99–110. https://doi.org/10.2967/jnumed.120.254110</mixed-citation><mixed-citation xml:lang="en">Vali R, Alessio A, Balza R, et al. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/ CT for Oncology 1.0. J Nucl Med. 2021;62(1):99–110. https://doi.org/10.2967/jnumed.120.254110</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Surti S. Radionuclide methods and instrumentation for breast cancer detection and diagnosis. Semin Nucl Med. 2013;43(4): 271–80. https://doi.org/10.1053/j.semnuclmed.2013.03.003</mixed-citation><mixed-citation xml:lang="en">Surti S. Radionuclide methods and instrumentation for breast cancer detection and diagnosis. Semin Nucl Med. 2013;43(4): 271–80. https://doi.org/10.1053/j.semnuclmed.2013.03.003</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Швецова ЮН, Ерина АА, Щукин ВМ и др. Определение методом масс-спектрометрии с индуктивно-связанной плазмой содержания элементных примесей в российских радиофармацевтических лекарственных препаратах. Регуляторные исследования и экспертиза лекарственных средств. 2025;15(4):434–43. https://doi.org/10.30895/1991-2919-2025-15-4-434-443</mixed-citation><mixed-citation xml:lang="en">Shvetsova YuN, Erina AA, Shchukin VM, et al. Detecting elemental impurities by inductively coupled plasma mass spectrometry in Russian radiopharmaceuticals. Regulatory Research and Medicine Evaluation. 2025;15(4):434–43 (In Russ.). https://doi.org/10.30895/1991-2919-2025-15-4-434-443</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kilian K, Chabecki B, Kiec J, et al. Synthesis, quality control and determination of metallic impurities in F-fludeoxyglucose production process. Rep Pract Oncol Radiother. 2014; 19(1):22–31. https://doi.org/10.1016/j.rpor.2014.03.001</mixed-citation><mixed-citation xml:lang="en">Kilian K, Chabecki B, Kiec J, et al. Synthesis, quality control and determination of metallic impurities in F-fludeoxyglucose production process. Rep Pract Oncol Radiother. 2014; 19(1):22–31. https://doi.org/10.1016/j.rpor.2014.03.001</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kilian K, Pęgier M, Pękal A, Pyrzyńska K. Distribution and separation of metallic and radionuclidic impurities in the production of 18F-fluorodeoxyglucose. J Radioanal Nucl Chem. 2016; (307):1037–43. https://doi.org/10.1007/s10967-015-4328-6</mixed-citation><mixed-citation xml:lang="en">Kilian K, Pęgier M, Pękal A, Pyrzyńska K. Distribution and separation of metallic and radionuclidic impurities in the production of 18F-fluorodeoxyglucose. J Radioanal Nucl Chem. 2016; (307):1037–43. https://doi.org/10.1007/s10967-015-4328-6</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tavares AT, Martins PDA, Fukumori NT, et al. Multielemental determination of trace elements in radiopharmaceuticals produced at the radiopharmacy center using ICP-OES technique. In: International Nuclear Atlantic Conference (INAC 2013). Recife, PE (Brazil); 2013.</mixed-citation><mixed-citation xml:lang="en">Tavares AT, Martins PDA, Fukumori NT, et al. Multielemental determination of trace elements in radiopharmaceuticals produced at the radiopharmacy center using ICP-OES technique. In: International Nuclear Atlantic Conference (INAC 2013). Recife, PE (Brazil); 2013.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Muller ALH, Oliveira JSS, Mello PA, et al. Study and determination of elemental impurities by ICP-MS in active pharmaceutical ingredients using single reaction chamber digestion in compliance with USP requirements. Talanta. 2015;136:161–9. https://doi.org/10.1016/j.talanta.2014.12.023</mixed-citation><mixed-citation xml:lang="en">Muller ALH, Oliveira JSS, Mello PA, et al. Study and determination of elemental impurities by ICP-MS in active pharmaceutical ingredients using single reaction chamber digestion in compliance with USP requirements. Talanta. 2015;136:161–9. https://doi.org/10.1016/j.talanta.2014.12.023</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Nicolaï M, Rosin C, Tousset N, Nicolai Y. Trace metals analysis in estuarine and seawater by ICP-MS using on line preconcentration and matrix elimination with chelating resin. Talanta. 1999;50(2):433–44. https://doi.org/10.1016/S0039-9140(99)00130-7</mixed-citation><mixed-citation xml:lang="en">Nicolaï M, Rosin C, Tousset N, Nicolai Y. Trace metals analysis in estuarine and seawater by ICP-MS using on line preconcentration and matrix elimination with chelating resin. Talanta. 1999;50(2):433–44. https://doi.org/10.1016/S0039-9140(99)00130-7</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Colon M, Hidalgo M, Iglesias M. Correction strategies over spectral interferences for arsenic determination in aqueous samples with complex matrices by quadrupole ICP-MS. J Anal At Spectrom. 2009;24(4):518–21. https://doi.org/10.1039/B820898K</mixed-citation><mixed-citation xml:lang="en">Colon M, Hidalgo M, Iglesias M. Correction strategies over spectral interferences for arsenic determination in aqueous samples with complex matrices by quadrupole ICP-MS. J Anal At Spectrom. 2009;24(4):518–21. https://doi.org/10.1039/B820898K</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Choe KY, Gajek R. Determination of trace elements in human urine by ICP-MS using sodium chloride as a matrix-matching component in calibration. Anal Methods. 2016;8(37):6754–63. https://doi.org/10.1039/c6ay01877g</mixed-citation><mixed-citation xml:lang="en">Choe KY, Gajek R. Determination of trace elements in human urine by ICP-MS using sodium chloride as a matrix-matching component in calibration. Anal Methods. 2016;8(37):6754–63. https://doi.org/10.1039/c6ay01877g</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kojo K, Oguri T, Tanaka T, et al. Inductively coupled plasma mass spectrometry performance for the measurement of key serum minerals: A comparative study with standard quantification methods. J Clin Lab Anal. 2025;39(2):e25140. https://doi.org/10.1002/jcla.25140</mixed-citation><mixed-citation xml:lang="en">Kojo K, Oguri T, Tanaka T, et al. Inductively coupled plasma mass spectrometry performance for the measurement of key serum minerals: A comparative study with standard quantification methods. J Clin Lab Anal. 2025;39(2):e25140. https://doi.org/10.1002/jcla.25140</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
